Sugarbaker Paul H
Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA.
Transl Lung Cancer Res. 2018 Oct;7(5):599-608. doi: 10.21037/tlcr.2018.08.03.
Malignant peritoneal mesothelioma (MPM) is a rare disease whose natural history is confined to the peritoneal space. Systemic chemotherapy has little impact on survival of patients with MPM. A surgical procedure with a goal of resection of all visible evidence of disease, called cytoreductive surgery (CRS) has been utilized in MPM patients. Also, regional chemotherapy with hyperthermic intraperitoneal chemotherapy (HIPEC) and normothermic intraperitoneal chemotherapy long-term (NIPEC-LT) have been effectively utilized in MPM patients. In the absence of CRS and HIPEC the median survival of MPM patients is approximately 1 year. The aggressive surgical approach plus regional chemotherapy has increased the median survival to more than 5 years. With NIPEC-LT added on, 70% 5-year survival has been reported. Knowledgeable patient selection for treatment is mandatory. The use of CRS, HIPEC and NIPEC-LT has greatly benefited patients with MPM. Global application of these treatments is indicated.
恶性腹膜间皮瘤（MPM）是一种罕见疾病，其自然病程局限于腹膜腔。全身化疗对MPM患者的生存影响甚微。一种旨在切除所有可见病灶的手术，即细胞减灭术（CRS）已应用于MPM患者。此外，热灌注腹腔化疗（HIPEC）和常温腹腔长期化疗（NIPEC-LT）也已有效地应用于MPM患者。在未进行CRS和HIPEC的情况下，MPM患者的中位生存期约为1年。积极的手术方法加上区域化疗已将中位生存期提高到5年以上。加上NIPEC-LT后，已有报道5年生存率达70%。必须对患者进行明智的治疗选择。CRS、HIPEC和NIPEC-LT的应用使MPM患者受益匪浅。这些治疗方法应在全球范围内应用。
